Proteolysis-targeting chimeras and their implications in breast cancer
Breast cancer (BC) is a highly heterogeneous neoplasm of the mammary tissue, causing the deaths of a large number of women worldwide. Nearly 70% and 20% of BC cases are estrogen receptor alpha positive (ERα+) and human epidermal growth factor receptor 2-positive (HER2+), respectively; therefore, ER...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2021-12-01
|
| Series: | Exploration of Targeted Anti-tumor Therapy |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/etat/Article/100260 |
| _version_ | 1819098458325254144 |
|---|---|
| author | Angeles C. Tecalco-Cruz Jesús Zepeda-Cervantes Josué O. Ramírez-Jarquín Alberto Rojas-Ochoa |
| author_facet | Angeles C. Tecalco-Cruz Jesús Zepeda-Cervantes Josué O. Ramírez-Jarquín Alberto Rojas-Ochoa |
| author_sort | Angeles C. Tecalco-Cruz |
| collection | DOAJ |
| description | Breast cancer (BC) is a highly heterogeneous neoplasm of the mammary tissue, causing the deaths of a large number of women worldwide. Nearly 70% and 20% of BC cases are estrogen receptor alpha positive (ERα+) and human epidermal growth factor receptor 2-positive (HER2+), respectively; therefore, ER and HER2 targeted therapies have been employed in BC treatment. However, resistance to these therapies has been reported, indicating a need for developing novel therapeutic strategies. Proteolysis-targeting chimeras (PROTACs) are new, promising therapeutic tools designed with a bimodular structure: one module allows specific binding to target proteins, and the other module allows efficient degradation of these target proteins. In this paper, PROTACs and their potential in controlling the progression of ERα and HER2+ BC are discussed. |
| first_indexed | 2024-12-22T00:31:18Z |
| format | Article |
| id | doaj.art-cde825929f7b48548b8659148429155f |
| institution | Directory Open Access Journal |
| issn | 2692-3114 |
| language | English |
| last_indexed | 2024-12-22T00:31:18Z |
| publishDate | 2021-12-01 |
| publisher | Open Exploration Publishing Inc. |
| record_format | Article |
| series | Exploration of Targeted Anti-tumor Therapy |
| spelling | doaj.art-cde825929f7b48548b8659148429155f2022-12-21T18:44:55ZengOpen Exploration Publishing Inc.Exploration of Targeted Anti-tumor Therapy2692-31142021-12-012649651010.37349/etat.2021.00060Proteolysis-targeting chimeras and their implications in breast cancerAngeles C. Tecalco-Cruz0https://orcid.org/0000-0001-9199-3834Jesús Zepeda-Cervantes1https://orcid.org/0000-0003-2069-2027Josué O. Ramírez-Jarquín2https://orcid.org/0000-0001-7574-8724Alberto Rojas-Ochoa3https://orcid.org/0000-0002-7115-9882Programa en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México (UACM), CDMX, Mexico City 03100, MexicoDepartamento de Microbiología e Inmunología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México (UNAM), CDMX, Mexico City 04510, MexicoInstituto de Fisiología Celular, Universidad Nacional Autónoma de México (UNAM), CDMX, Mexico City 04500, MexicoInstituto Nacional de Pediatría (INP), CDMX, Mexico City 04530, MexicoBreast cancer (BC) is a highly heterogeneous neoplasm of the mammary tissue, causing the deaths of a large number of women worldwide. Nearly 70% and 20% of BC cases are estrogen receptor alpha positive (ERα+) and human epidermal growth factor receptor 2-positive (HER2+), respectively; therefore, ER and HER2 targeted therapies have been employed in BC treatment. However, resistance to these therapies has been reported, indicating a need for developing novel therapeutic strategies. Proteolysis-targeting chimeras (PROTACs) are new, promising therapeutic tools designed with a bimodular structure: one module allows specific binding to target proteins, and the other module allows efficient degradation of these target proteins. In this paper, PROTACs and their potential in controlling the progression of ERα and HER2+ BC are discussed.https://www.explorationpub.com/Journals/etat/Article/100260estrogen receptor alphabreast cancerdegradation via the ubiquitin-proteasome systemproteolysis-targeting chimeras |
| spellingShingle | Angeles C. Tecalco-Cruz Jesús Zepeda-Cervantes Josué O. Ramírez-Jarquín Alberto Rojas-Ochoa Proteolysis-targeting chimeras and their implications in breast cancer Exploration of Targeted Anti-tumor Therapy estrogen receptor alpha breast cancer degradation via the ubiquitin-proteasome system proteolysis-targeting chimeras |
| title | Proteolysis-targeting chimeras and their implications in breast cancer |
| title_full | Proteolysis-targeting chimeras and their implications in breast cancer |
| title_fullStr | Proteolysis-targeting chimeras and their implications in breast cancer |
| title_full_unstemmed | Proteolysis-targeting chimeras and their implications in breast cancer |
| title_short | Proteolysis-targeting chimeras and their implications in breast cancer |
| title_sort | proteolysis targeting chimeras and their implications in breast cancer |
| topic | estrogen receptor alpha breast cancer degradation via the ubiquitin-proteasome system proteolysis-targeting chimeras |
| url | https://www.explorationpub.com/Journals/etat/Article/100260 |
| work_keys_str_mv | AT angelesctecalcocruz proteolysistargetingchimerasandtheirimplicationsinbreastcancer AT jesuszepedacervantes proteolysistargetingchimerasandtheirimplicationsinbreastcancer AT josueoramirezjarquin proteolysistargetingchimerasandtheirimplicationsinbreastcancer AT albertorojasochoa proteolysistargetingchimerasandtheirimplicationsinbreastcancer |